Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.
3.
4.
5.

The role of databases in drug postmarketing surveillance.

Rodriguez EM, Staffa JA, Graham DJ.

Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):407-10.

PMID:
11802586
6.

Automated support for pharmacovigilance: a proposed system.

Bright RA, Nelson RC.

Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):121-5.

PMID:
11998536
8.

Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.

Ferranti J, Horvath MM, Cozart H, Whitehurst J, Eckstrand J.

Pediatrics. 2008 May;121(5):e1201-7. doi: 10.1542/peds.2007-2609.

PMID:
18450863
9.

Spontaneous adverse event signaling methods: classification and use with health care treatment products.

Clark JA, Klincewicz SL, Stang PE.

Epidemiol Rev. 2001;23(2):191-210. Review.

PMID:
12192733
10.
11.

The US drug safety system: role of the pharmaceutical industry.

Gibson BR, Suh R, Tilson H.

Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):110-4.

PMID:
17724741
12.

Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.

Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW.

Arch Intern Med. 2007 May 28;167(10):1041-9.

PMID:
17533207
13.

Early detection of adverse drug events within population-based health networks: application of sequential testing methods.

Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R.

Pharmacoepidemiol Drug Saf. 2007 Dec;16(12):1275-84.

PMID:
17955500
14.

Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?

Trifirò G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, Bonhoeffer J, Schuemie M, van der Lei J, Sturkenboom M.

J Intern Med. 2014 Jun;275(6):551-61. doi: 10.1111/joim.12159. Review.

15.

Safety monitoring of new anti-malarials in immediate post-marketing phase.

Edwards IR.

Med Trop (Mars). 1998;58(3 Suppl):93-6. Review.

PMID:
10212911
16.

Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.

Brown JS, Kulldorff M, Petronis KR, Reynolds R, Chan KA, Davis RL, Graham D, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R.

Pharmacoepidemiol Drug Saf. 2009 Mar;18(3):226-34. doi: 10.1002/pds.1706.

PMID:
19148879
17.

Monitoring drug product quality.

Bolger G, Goetsch R, Reinstein P.

Am Pharm. 1992 Feb;NS32(2):47-9. No abstract available. Erratum in: Am Pharm 1992 Apr;NS32(4):6.

PMID:
1546630
19.

Early postmarketing drug safety surveillance: data mining points to consider.

Hauben M.

Ann Pharmacother. 2004 Oct;38(10):1625-30. Epub 2004 Aug 10.

PMID:
15304626
20.

Decision support methods for the detection of adverse events in post-marketing data.

Hauben M, Bate A.

Drug Discov Today. 2009 Apr;14(7-8):343-57. doi: 10.1016/j.drudis.2008.12.012. Epub 2009 Jan 31. Review.

PMID:
19187799

Supplemental Content

Support Center